SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Sarah Silbiger/Getty Images
FDA
FDA Approves First-Ever ADC in Platinum-Resistant Ovarian Cancer (Updated)
ImmunoGen’s Elahere was approved Monday under the FDA’s accelerated pathway for patients who have received one to three previous lines of systemic therapy.
November 15, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Satsuma’s Headaches Mount as Migraine Candidate Flops in Phase III
Topline results from the Phase III SUMMIT trial showed Satsuma Pharmaceuticals’ migraine candidate STS101 did not meet its primary efficacy endpoint.
November 14, 2022
 · 
2 min read
 · 
Tristan Manalac
Grand Warszawski / Shutterstock
Drug Development
Biogen-Eisai Solidly in the Lead After Roche’s Alzheimer’s Drug Misses in Phase III
Roche announced its investigational antibody gantenerumab failed to meet the primary endpoints in GRADUATE I and II - two Phase III studies in Alzheimer’s disease.
November 14, 2022
 · 
3 min read
 · 
Tristan Manalac
Bodo Marks/picture alliance via Getty
FDA
AstraZeneca Keeps the Pressure on in NSCLC with Imfinzi/Imjudo Nod (Updated)
The FDA approved AstraZeneca’s Imfinzi in combination with Imjudo and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer.
November 11, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Seagen Caps Busy Week with FDA Nod in Pediatric Hodgkin Lymphoma
Seagen’s Adcetris has been given FDA approval for the treatment of children aged two years and above with high-risk classical Hodgkin lymphoma.
November 11, 2022
 · 
1 min read
 · 
Tristan Manalac
Shutterstock
Business
Reports: Neuro-Focused Faze Medicines to Shutter Operations
Third Rock-founded Faze Medicines appears to be shuttering operations, with several former employees signaling they are looking for new jobs.
November 10, 2022
 · 
2 min read
 · 
Tristan Manalac
Jonathan Weiss/Shutterstock
Drug Development
FDA Adcomm Backs AstraZeneca’s Asthma Drug for Adults, but not Children
The FDA deemed AstraZeneca’s PT027 to have a favorable risk-benefit profile for treating asthma in patients aged 18 or older but was less keen on supporting the drug in younger populations.
November 9, 2022
 · 
3 min read
 · 
Tristan Manalac
Businessperson Walking Out With Exit Sign On Wall
Business
Adaptimmune Slashes 25% of Headcount Despite Improved Data for T-Cell Candidate - Updated
Adaptimmune has had a manic Tuesday, touting improved efficacy numbers for its T-cell candidate while also dealing with economic repercussions of its terminated partnership with GSK.
November 9, 2022
 · 
2 min read
 · 
Tristan Manalac
Muhammad Al-Hajj_IO Biotech/Pete DeMuth_Elicio The
Drug Development
80% of Patients in Investigational Breast Cancer Vaccine Trial Alive after 10 Years
Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.
November 8, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Abbvie Inc.
Drug Development
AbbVie Touts Subgroup Data in Phase II Atrial Fibrillation Miss
AbbVie’s investigational neurotoxin, designed to prevent postoperative atrial fibrillation, missed the primary endpoint in a Phase II trial, the company announced Monday.
November 8, 2022
 · 
2 min read
 · 
Tristan Manalac
Shot of a young woman getting her eye’s examined with a slit lamp
Deals
Viatris Acquires Oyster Point, Gains Access to Ophthalmic Pipeline
Eye specialist Oyster Point Pharma announced is being acquired by Viatris Inc. after Oyster’s board of directors unanimously signed off on the deal, Oyster Point announced Monday.
November 7, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Cristina Arias/Getty Images
Drug Development
Boehringer Ingelheim and Lilly’s Jardiance Scores in Late-Stage CKD Trial
Eli Lilly’s and Boehringer’s Jardiance met its primary outcome in the Phase III EMPA-KIDNEY study, the largest and broadest SGLT2 inhibitor trial in chronic kidney disease.
November 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
PDUFA for Apellis’ Geographic Atrophy NDA Delayed by Three Months
Apellis is submitting additional 24-month efficacy data to supplement the NDA for its intravitreal candidate pegcetacoplan for GA secondary to AMD.
November 4, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Emalex Closes $250M Series D to Fund Phase III Trial in Tourette Syndrome
Emalex Biosciences closed a Series D funding round Thursday counting $250 million in earnings, much of which will bankroll a Phase III trial of ecopipam for Tourette syndrome.
November 3, 2022
 · 
2 min read
 · 
Tristan Manalac
Asian woman holding cardboard box containing personal belongings after being fired by employer
Business
Surface Oncology Pauses CD39 Program, Slashes Workforce by 20%
Surface Oncology announced it is pausing the development of its CD39-targeted antibody SRF617 and cutting around 20% of its workforce to focus on its lead anti-IL-27 program SRF388.
November 2, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More